REFERENCES
1. M.A. Lui, Immunol. Rev. 239, 62–84 (2010).
2. "West Nile-Innovator DNA", Fort Dodge Animal Health. E0257D 15M AP (Nov. 2008).
3. N.C. Simard, "The Road to Licensure of a DNA Vaccine for Atlantic Salmon",
http://www.bion.no/filarkiv/2010/07/vaccine_simard.pdf, accessed Aug. 2011.
4. S. Vasan et al., PLoS One 6 (5), e19252 (2011).
5. K.E. Broderick et al., Hum. Vaccines 7, 22–28 (2011).
6. T. Kardos. "Contactless Magnetic Electroporation" presented at the DNA Vaccines Conference (San Diego, CA, 2011).
7. M.R. Prausnitz et al., Microbiol. Immunol. 333, 369–393 (2009).
8. J.W. Hooper et al., Vaccine 25, 1814–1823 (2007).
9. A.K. Roos et al., Mol. Ther. 13 (2), 320–327 (2006).
10. L.A. Hirao et al., J. Infect. Dis. 203 (1), 95–102 (2011).
11. D.J. Laddy et al., J. Virol. 83 (9), 4624–4630 (2009).
12. P.T. Loudon et al., PLoS One 5 (6), PLoS ONE doi:10.1371/journal.pone.0011021, Jun. 8, 2010.
13. M.A. Kutzler and D.B. Weiner, Nature Rev. Genetics 9, 776–788 (2008).
14. M. Shata et al., Mol. Med. Today 6, 66–71 (2000).
15. P.M. Smooker et al., Biotechnol Annual Rev. 10, 189–236 (2004).
16. G. Dietrich, A. Collioud, and S.A. Rothen. Biopharm Intl. 21 (10) s6–s14 (2008).
17. A. Edwards and N.K.H. Slater, Vaccine 27, 3897–3903 (2009).
18. FDA, Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information. (Rockville, MD, Sept. 2010).
19. J.M. Huang et al., Vaccine 28, 7523–7528 (2010).
20. J. Bergin, "DNA Vaccines: Technologies and Global Markets," BCC Research (2009)
|
